Data from FDA - Curated by EPG Health - Last updated 20 December 2016
As with other anticonvulsants,
Abrupt withdrawal of anticonvulsant medication may precipitate
Methsuximide, when used alone in mixed types of epilepsy, may increase the frequency of grand mal seizures in some patients.
Information for Patients Inform patients of the availability of a Medication Guide, and instruct them to read the Medication Guide prior to taking Celontin.
Instruct patients to take Celontin only as prescribed.
Patients taking methsuximide should be advised of
Patients should be instructed to
ADVICE TO THE PHARMACIST AND PATIENT: Since
Do not dispense or use capsules that are not full or in which
Patients, their caregivers, and families should be counseled that AEDs, including Celontin, may increase the risk of
This registry is collecting information about the
To enroll, patients can call
Drug Interactions Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).
Pregnancy To provide information regarding the effects of in utero exposure to Celontin,
This can be done by calling
Information on the registry can also be found at the website: http://www.aedpregnancyregistry.org/.
See WARNINGS. Pediatric Use See DOSAGE AND ADMINISTRATION.
Hemopoietic System: Hemopoietic
Drowsiness, ataxia, and dizziness have been the most frequent side effects noted.
There have been
Integumentary System: Dermatologic manifestations which have occurred with the administration of methsuximide have included urticaria, Stevens-Johnson syndrome, and pruritic erythematous rashes.
Genitourinary System: Proteinuria, microscopic hematuria.
Body as a Whole: Periorbital edema.
DOSAGE AND ADMINISTRATION Optimum dosage of Celontin must be determined by trial.
A suggested dosage schedule is 300 mg per day for the first week.
Celontin may be administered in combination with other anticonvulsants when other forms of epilepsy coexist with
|Agency product number||0G76K8X6C0|
|Date Last Revised||25-07-2014|
|Type||HUMAN PRESCRIPTION DRUG|
|Storage and handling||Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature]. Protect from light and moisture. Protect from excessive heat 40°C (104°F).|
|Marketing authorisation holder||Parke-Davis Div of Pfizer Inc|